Q&A: Acelyrin CEO Shao-Lee Lin details biotech’s $540M IPO, finding ‘diamonds in the rough’

Acelyrin started trading on the Nasdaq Friday morning in one of the largest biotech initial public offerings in recent memory, with $540 million in gross proceeds and potentially $621 million if underwriters exercise their 30-day option to buy more shares.